Modern view on mechanisms of uric acid nephrolithiasis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review analyzes modern concepts of the pathophysiological mechanisms of uric acid nephrolithiasis. It specifies the main factors contributing to the formation of uric acid stones in the kidney. It is noted that the formation of kidney stones, comprising uric acid, depends on low urine production, hyperuricosuria and, primarily, on the degree of urine acidification.Conditions accompanied by a prolonged decline in urinary pH, and first of all metabolic syndrome and its components such as insulin resistance and obesity associated with the greatest risk of uric acid kidney stone formation.

全文:

受限制的访问

作者简介

Ja. Zverev

Email: ZVER@ASMU.RU

V. Brjuhanov

参考

  1. Барскова В.Г., Мукагова М.В. Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Совр. ревматол. 2011; 5(4): 39-43.
  2. Mandel N.S., Mandel G.S. Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J. Urol. 1989; 142: 1516-1521.
  3. Gault M.H., Chafe L. Relationship of frequency, age, sex, stone, weight, and composition in 15,624 stones: comparison of results for 1980 to 1993 and 1995 to 1998. J. Urol. 2000; 164: 302-307.
  4. Bushinsky D.A. Kidney stones. Adv. Intern. Med. 2001; 47: 219-238.
  5. Maalouf N.M., Cameron M.A., Moe O.W., Sakhaee K. Novel insights into pathogenesis of uric acid nephrolithiasis. Curr. Opin. Nephrol. Hypertens. 2004; 13(2): 181-189.
  6. Liebman S.E., Taylor J.G., Bushinsky D.A. Uric acid nephrolithiasis. Curr. Rheumatol. Rep. 2007; 9(3): 251-257.
  7. Ngo T.C., Assimos D.G. Uric acid nephrolithiasis: recent progress and future directions. Rev. Urol. 2007; 9(1): 17-27.
  8. Daudon M., Traxer O., Conort P., Lacour B., Jungers P. Type 2 diabetes increases the risk for uric acid stones. J. Am. Soc. Nephrol. 2006; 17(7): 2026-2033.
  9. Саенко В.С., Винаров А.З., Песегов С.В. Гиперурикемия - маркер риска эндотелиальной дисфункции в развитии эректильной дисфункции. Урология. 2014; 4: 100-103.
  10. Grenabo L., Hedelin H., Pettersson S. The severity of infection stones compared to other stones in the upper urinary tract. Scand. J. Urol. Nephrol. 1985; 19: 285-289.
  11. Shekarriz B., Stoller M.L. Uric acid nephrolithiasis: current concepts and controversies. J. Urol. 2002; 168: 1307-1314.
  12. Hossain R.Z., Ogawa Y., Hokama S., Morozumi M., Hatano T. Urolithiasis in Okinawa, Japan: a relatively high prevalence of uric acid stones. Int. J. Urol. 2003; 10: 411-415.
  13. Ansari M.S., Gupta N.P., Hemal A.K., Dogra P.N., Seth A., Aron M., Singh T.P. Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India. Int. J. Urol. 2005; 12: 12-16.
  14. Portis A.J., Hermans K., Culhane-Pera K.A., Curhan G.C. Stone diseased in the Hmong of Minnesota: initial description of a high-risk population. J. Endourol. 2004; 18: 853-857.
  15. Maloney M.E., Springhart W.P., Ekeruo W.O., Young M.D., Enemchukwu C.U., Preminger G.M. Ethnic background has minimal impact on the etiology of nephrolithiasis. J. Urol. 2005; 173: 2001-2004.
  16. Gentle D.L., Stoller M.L., Bruce J.E., Leslie S.W. Geriatric urolithiasis. J. Urol. 1997; 158: 2221-2224.
  17. Robertson W.G., Peacock M., Heyburn P.J., Hanes F.A. Epidemiological risk factors in calcium stone disease. Scand. J. Urol. Nephrol. Suppl. 1980; 53: 15-30.
  18. Goldfarb D.S., Parks J.H., Coe F.L. Renal stone disease in older adults. Clin Geriatr. Med. 1998;14:367-381.
  19. Daudon M., Dore J.C., Jungers P., Lacour B. Changes in stone composition according to age and gender of patients: A multivariate epidemiological approach. Urol. Res. 2004; 32: 241-247.
  20. Henneman P.H., Wallach S., Dempsey E.F. The metabolism defect responsible for uric acid stone formation. J. Clin. Invest. 1962; 41: 537-542.
  21. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003; 112: 1821-1830.
  22. Pak C.Y., Sakhaee K., Peterson R.D., Poindexter J.R., Frawley W.H. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001; 60: 757-761.
  23. Sakhaee K., Maalouf N.M. Metabolic syndrome and uric acid nephrolithiasis. Semin. Nephrol. 2008; 28(2): 174-180.
  24. Зверев Я.Ф., Брюханов В.М., Лампатов В.В., Жариков А.Ю. Современные представления о роли физико-химических факторов в патогенезе кальциевого нефролитиаза. Нефрология. 2009; 13(1): 39-50.
  25. Брюханов В.М.,Зверев Я.Ф., Лампатов В.В., Мотина Н.В., Жариков А.Ю., Кудинов А.В. Влияние питьевых режимов на движущие силы кристаллизации при экспериментальном нефролитиазе. Урология 2011; 1: 6-11.
  26. Borghi L., Meschi T., Amato F., Novarini A., Romanelli A., Cigala F. Hot occupation and nephrolithiasis. J. Urol. 1993; 150: 1757-1760.
  27. el-Reshaid K., Mughal H., Kapoor M. Epidemiological profile, mineral metabolic pattern and crystallographic analysis of urolithiasis in Kuwait. Eur. J. Epidemiol. 1997; 13: 229-234.
  28. Robertson W.G. Renal stones in the tropics. Semin. Nephrol. 2003; 23: 77-87.
  29. Atan L., Andreoni C., Ortiz V., Silva E.K., Pitta R., Atan F., Srougi M. High kidney stone risk in men working in steel industry at hot temperatures. Urology. 2005; 65: 858-861.
  30. Grossman M.S., Nugent F.W. Urolithiasis as a complication of chronic diarrheal disease. Am. J. Dig. Dis. 1967; 12: 491-498.
  31. Gelzayd E.A., Breuer R.I., Kirsner J.B. Nephrolithiasis in inflammatory bowel disease. Am. J. Dig. Dis. 1968; 13: 1027-1034.
  32. McLeod R.S., Churchill D.N. Urolithiasis complicating inflammatory bowel disease. J. Urol. 1992; 148: 974-978.
  33. Жариков А.Ю., Зверев Я.Ф., Брюханов В.М., Лампатов В.В. Современные представления о модуляторах оксалатного нефролитиаза. I. Стимуляторы кристаллизации. Нефрология. 2009; 13(1): 56-72.
  34. Зверев Я.Ф., Жариков А.Ю., Брюханов В.М., Лампатов В.В. Модуляторы оксалатного нефролитиаза. Ингибиторы кристаллизации. Нефрология. 2010; 14(1): 24-49.
  35. Grases F., Ramis M., Villacampa A.I., Costa-Bauza A. Uric acid urolithiasis and crystallization inhibitors. Urol. Int. 1999; 62: 201-204.
  36. Koka R.M., Huang E., Lieske J.C. Adhesion of uric acid crystals to the surface of renal epithelial cells. Am. J. Physiol. 2000; 278: F989-F998.
  37. Ombra M.N., Casula S., Biino G., Maestrale G., Cardia F., Melis P., Pirastu M. Urinary glycosaminoglycans as risk factors for uric acid nephrolithiasis: case control study in a Sardinian genetic isolate. Urology. 2003; 62: 416-420.
  38. Maalouf N.M. Metabolic syndrome and the genesis of uric acid stones. J. Ren. Nutr. 2011; 21(1): 128-131.
  39. Yu T.F., Gutman A.B. Uric acid nephrolithiasis in gout. Ann. Intern. Med. 1967; 67: 1133-1148.
  40. Kramer H., Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am. J. Kidney Dis. 2002; 40: 37-42.
  41. Kramer H.J., Choi H.K., Atkinson K., Stampfer M., Curhan G.C. The association between gout and nephrolithiasis in men: The Health Professional’s Follow-Up Study. Kidney Int. 2003; 64: 1022-1026.
  42. Alvarez-Nemegyei J., Medina-Escobedo M., Villanueva-Jorge S., Vasquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a КЛИНИЧЕСКАЯ нефрология № 5-6 - 2015 reappraisal needed? J. Rheumatol. 2005; 32: 2189-2191.
  43. Campion E., Glynn R., DeLabry L. Asymptomatic hyperuricemia: risks and consequences in the in the Normative Aging Study. Am. J. Med. 1987; 82: 421-426.
  44. Terkeltaub R.A. Clinical practice. Gout. N. Engl. J. Med. 2003; 349: 1647-1655.
  45. Pak C.Y., Sakhaee K., Moe O., Preminger G.M., Poindexter J.R., Peterson R.D., Pietrow P., Ekeruo W. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003; 61: 523-527.
  46. Terkeltaub R., Bushinsky D., Becker M. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res. Ther. 2006; 8: S4.
  47. Пытель Ю.А., Золотарев И.И. Уратный нефролитиаз. М.: Медицина, 1995.
  48. Mullin J.W. Nucleation. In: Crystallization. Butterworth-Heinemann, Oxford, 1993. P. 172-201.
  49. Yu T.F. Urolithiasis in hyperuricemia and gout. J. Urol. 1981; 126: 424-430.
  50. Enomoto A., Kimura H., Chairoungdua A., Shigeta Y., Jutabha P., Cha S.H., Hosoyamada M., Takeda M., Sekine T., Igarashi T., Matsuo H., Kikuchi Y., Oda T., Ichida K., Hosoya T., Shimokata K., Niwa T., Kanai Y., Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002; 417(6887): 447-452.
  51. Enomoto A., Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin. Exp. Nephrol. 2005; 9: 195-205.
  52. WakidaN., Tuyen do G.,AdachiM., Miyoshi T., NonoguchiH., OkaT., Ueda O., Tazawa M., Kurihara S., Yoneta Y., Shimada H., Oda T., Kikuchi Y., Matsuo H., Hosoyamada M., Endou H., Otagiri M., Tomita K., Kitamura K. Mutations in human urate transporter 1 gene in presecretory reabsorption defect type of familial renal hypouricemia. J. Clin. Endocrinol. Metab. 2005; 90: 2169-2174.
  53. So A., Thorens B. Uric acid transport and disease. J. Clin. Invest. 2010; 120(6): 1791-1799.
  54. Anzai N., Jutabha P. Recent advances of renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin. Exp. Nephrol. 2012; 16: 89-95.
  55. Bobulescu I.A., Moe O.W. Renal transport of uric acid: evolving concepts and uncertainties. Adv. Chronic Kidney Dis. 2012; 19(6): 358-371.
  56. Lipkowitz M.S. Regulation of uric acid excretion by the kidney. Curr. Rheumatol. Rep. 2012; 14: 179-188.
  57. Breslau N.A., Brinkley L., Hill K.D., Pak C.Y. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J. Clin. Endocrinol. Metab. 1988; 66: 140-146.
  58. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Ka T., Fukuchi M., Hada T. Effect of beer on the plasma concentrations of uridine and purine bases. Metabolism. 2002; 51: 1317-1323.
  59. Choi H.K., Atkinson K., Karlson E.W., Willett W., Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004; 363: 1277-1281.
  60. Choi H.K., Atkinson K., Karlson E.W., Willett W., Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med. 2004; 350(11): 1093-2003.
  61. Villegas R., Xiang Y.B., Elasy T., Xu W.H., Cai H., Cai Q., Linton M.F., Fazio S., Zheng W., Shu X.O. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutr. Metab. Cardiovasc. Dis. 2011; 22: 409-416.
  62. Torralba K.D., De Jesus E., Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. Int. J. Rheum. Dis. 2012; 15: 499-506.
  63. Endou H., Anzai N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids. 2008; 27: 578-584.
  64. Richette P., Garay R. Novel drug discovery strategies for gout. Expert Opin. Drug Discov. 2013; 8(2): 183-189.
  65. Bach M.H., Simkin P.A. Uricosuric drugs: the once and future therapy for hyperuricemia? Curr. Opin. Rheumatol. 2014; 26(2): 169-175.
  66. Sica D., Schoolwerth A.C. Part 1. Uric acid and losartan. Curr. Opin. Nephrol. Hypertens. 2002; 11: 475-482.
  67. Feher M.D., Hepburn A.L., Hogarth M.B., Ball S.G., Kaye S.A. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford). 2003; 42: 321-325.
  68. Milionis H.J., Kakafika A.I., Tsouli S.G., Athyros V.G., Bairaktari E.T., Seferiadis K.I., Elisaf M.S. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am. Heart J. 2004; 148: 635-640.
  69. Кадыров З.А., Истратов В.Г., Сулейманов С.И. Некоторые вопросы этиологии и патогенеза мочекаменной болезни. Урология. 2006; 5: 98-102.
  70. Martillo M.A., Nazzal L., Crittenden D.B. The crystallization of monosodium urate. Curr. Rheumatol. Rep. 2014; 16(2): 400.
  71. Menon M., Resnick M.I. Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh P.C., eds. Campbell’s Urology, 8th ed. Saunders, Philadelphia, 2002. P. 3229-3305.
  72. Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009; 75(6): 585-595.
  73. Вандер А. Физиология почек. Под ред. Ю.В. Наточина. СПб.: Питер, 2000.
  74. Nagami G.T. Renal ammonia production and excretion. In: Seldin D.W., Giebisch G., eds. The Kidney: Physiology and Pathophysiology. Philadelphia, PA: Lippincott Williams & Wilkin, 2000. P. 1995-2014.
  75. Curthoys N.P. Renal ammonium ion production and excretion. In: Alpern R.J., Caplan M., Moe O.W., eds. Seldin and Giebisch’s The Kidney Physiology and Pathophysiology. San Diego, CA: Academic Press, 2013. P. 1995-2019.
  76. Kinsella J.L., Aronson P.S. Interaction of NH4+ and Li+ with the renal microvillus membrane Na+-H+ exchanger. Am. J. Physiol Cell. Physiol 1981; 241: C220-C226.
  77. Nagami G.T. Luminal secretion of ammonia in the mouse proximal tubule perfused in vitro. J. Clin. Invest. 1988; 81: 159-164.
  78. Nagami G.T. Ammonia production and secretion by the proximal tubule. Am. J. Kidney Dis. 1989; 14: 258-261.
  79. Sakhaee K., Adams-Huet B., Moe O.W., Pak C.Y.C. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002; 62: 971-979.
  80. Kamel K.S., Cheema-Dhadli S., Halperin M.L. Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney Int. 2002; 61: 988-994.
  81. Asplin J.R. Uric acid stones. Semin. Nephrol. 1996; 16(5): 412-424.
  82. Маколкин В.И., Напалков Д.А. Метаболический синдром: современные представления. М.: Миклош, 2012.
  83. Бокарев И.Н. Метаболический синдром. Клин. мед. 2014; 92(8): 71-76.
  84. Шостак Н.А., Аничков Д.А. К вопросу о диагностике и критериях метаболического синдрома. РМЖ. 2002; 27: 1255-1257.
  85. Шостак Н.А., Аничков Д.А. Метаболический синдром: критерии диагностики и возможности антигипертензивной терапии. РМЖ. 2002; 27: 1258-1261.
  86. Лубяко Е.А. Метаболический синдром: современный взгляд. Вестн. угроведения. 2014; 1(16): 154-158.
  87. Reaven G.M. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-1607.
  88. Елисеев М.С., Барскова В.Г. Метаболический синдром при подагре. Вестник РАМН. 2008; 6: 29-32.
  89. Калашникова М.Ф. Метаболический синдром: современный взгляд на концепцию, методы профилактики и лечения. Эффективная фармакотерапия. 2013; 52: 52-63.
  90. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005; 365: 1415-1428.
  91. Kim Y.-J., Kim C.-H., Sung E.-J., Kim S.R., Shin H.C., Jung W.J. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism. 2013; 62(6): 808-813.
  92. БарсковаВ.Г., Насонова В.А. Подагра и синдром инсулинорезистентности. РМЖ. 2013; 11(23): 1299-1301.
  93. Закирова В.Б. Метаболический синдром, гиперурикемия и подагра. Практич. мед. 2010; 5(44): 27-31.
  94. Антипова В.Н., Казеева М.В. Кардиоваскулярный риск и метаболический синдром у больных подагрой. Известия высших учебных заведений. Поволжский регион. Медицинские науки. 2015; 1(33): 112-122.
  95. Choi H.K., Ford E.S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 2007; 120: 442-447.
  96. Chien K.L., Chen M.F., Hsu H.C., Chang W.T., Su T.C., Lee Y.T., Hu F.B. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin. Chem. 2008; 54: 310-316.
  97. Bhole V., Choi J.W., Kim S.W., de Vera M., Choi H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am. J. Med. 2010; 123: 957-961.
  98. Dao H.H., Harun-Or-Rashid M., Sakamoto J. Body composition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology 2010; 49: 2400-2407.
  99. Барскова В.Г., Елисеев М.С., Денисов И.С., Елисеева М.Е., Беликов О.А., Фадиенко Г.Р., Жарская Ф.С., Полковникова О.П., Калягин А.Н., Склянова М.В., Швецова Е.А., Князева Л.А., Марусенко И.М., Мясоедова С.Е., Кожевникова Е.А., Петрова М.Н., Раскина Т.А., Королева М.В., Тыренко В.В., Алнувайрах А.А., Ханов А.Г. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Научно-практич. ревматол. 2012; 50(6): 15-18.
  100. Мухин Н., Козловская Л., Моисеев С., Балкаров И., Лопаткина Т., Фомин В. Секреты метаболического синдрома. Врач. 2005; 4: 8-14.
  101. Калинченко С.Ю., Тюзиков И.А. Метаболический синдром и уролитиаз (литературный обзор). Алфавит. 2011; 3(16): 33-40.
  102. Akman T., Binbay M., Erbin A., Tepeler A., Sari E., Kucuktopcu O., Ozgor F., Muslumanoglu A. The impact of metabolic syndrome on long-term outcomes of percutaneous nephrolithotomy (PCNL). BJU Int. 2012; 110: E1079-E1083.
  103. Cho S.T., Jung S.I., Myung S.C., Kim T.H. Correlation of metabolic syndrome with urinary stone composition. Int. J. Urol. 2013; 20: 208-213.
  104. Meydan N., Barutca S., Caliskan S., Camsari T. Urinary stone disease in diabetes mellitus. Scand. J. Urol. Nephrol. 2003; 27: 64-70.
  105. Taylor E.N., Stampfer M.J., Curhan G.C. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005; 68: 1230-1235.
  106. Ekeruo W.O., Tan Y.H., Young M.D., Dahm P., Maloney M.E., Mathias B.J., Albala D.M., Preminger G.M. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J. Urol. 2004; 172: 159-163.
  107. Bobulescu I.A., Maalouf N.M., Capolongo G., Adams-Huet B., Rosenthal T.R., Moe O.W., Sakhaee K. Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am. J. Physiol. Renal Physiol. 2013; 305: E1498-E1503.
  108. Facchini F., Chen Y.D., Hollenbeck C.B., Reaven G.M. Relationship be-tween resistance to insulin-mediated glucose uptake, urinary uric acid clear-ance, and plasma uric acid concentration. JAMA. 1991; 266: 3008-3011.
  109. Cappuccio F.P., Strazzullo P., Farinaro E., Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA. 1993; 270: 354-359.
  110. Li H., Klett D.E., Littleton R., Sammon J.D. Role of insulin resistance in uricacid nephrolithiasis. World J. Nephrol. 2014; 3(4): 237-242.
  111. Abate N., Chandalia M., Cabo-Chan A.V. Jr., Moe O.W., Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004; 65: 386-392.
  112. Cameron M.A., Maalouf N.M., Adams-Huet B., Moe O.W., Sakhaee K. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J. Am. Soc. Nephrol. 2006; 17: 1422-1428.
  113. Meezan E., Freychet P. Specific insulin receptors in rat renal glomeruli. Ren. Physiol. 1980; 3: 72-78.
  114. Nakamura R., Emmanouel D.S., Katz A.I. Insulin binding sites in various segments of the rabbit nephron. J. Clin. Invest. 1983; 72: 388-392.
  115. Klisic J., Hu M.C., Nief V., Reyes L., Fuster D., Moe O.W., Ambühl P.M. Insulin activated Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. Am. J. Physiol. 2002; 283: F532-F539.
  116. Fuster D.G., Bobulescu I.A., Zhang J., Wade J., Moe O.W. Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin. Am. J. Physiol 2007; 292: F577-F585.
  117. Chobanian M.C., Hammerman M.R. Insulin stimulates ammoniagenesis in canine renal proximal tubular segments. Am. J. Physiol 1987; 253: F1171-F1177.
  118. Krivosikova Z, Spustova V., Dzurik R. Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Physiol Res. 1998; 47: 177-183.
  119. Nissim I., States B., Nissim I., Lin Z.P., Yudkoff M. Hormonal regulation of glutamine metabolism by OK cells. Kidney Int. 1995; 47: 96-105.
  120. Nielsen S.J., Popkin B.M. Patterns and trends in food portion sizes, 19771998. JAMA. 2003; 289: 450-453.
  121. Cordian L., Eaton S.B., Sebastian A., Mann N., Lindeberg S., Watkins B.A., O'Keefe J.H., Brand-Miller J. Origins and evolution of the Western diet: Health implications for the 21st century. Am. J. Clin. Nutr. 2005; 81: 341-354.
  122. Despres J.P. Our passive lifestyle, our toxic diet, and the atherogen-ic/ diabetogenic metabolic syndrome: Can we afford to be sedentary and unfit? Circulation. 2005; 112: 453-455.
  123. Lee Y., Hirose H., Ohneda M., Johnson J.H., McGarry J.D., Unger R.H. Betacell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl. Acad. Sci. USA. 1994; 91: 10878-10882.
  124. Bachmann O.P., Dahl D.B., Brechtel K., Machann J., Haap M., Maier T., Loviscach M., Stumvoll M., Claussen C.D., Schick F., Häring H.U., Jacob S. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes. 2001; 50: 2579-2584.
  125. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002; 51: 7-18.
  126. Szczepaniak L.S., Dobbins R.L., Metzger G.J., Sartoni-DAmbrosia G., Arbique D., Vongpatanasin W., Unger R., Victor R.G. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 2003; 49: 417-423.
  127. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., Hobbs H.H., Dobbins R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. 2005; 288: E462-E468.
  128. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-1395.
  129. McGavock J.M., Victor R.G., Unger R.H., Szczepaniak L.S.; American College of Physicians and the American Physiological Society. Adiposity of the heart, revisited. Ann. Intern. Med. 2006; 144: 517-524.
  130. Вялкова А.А., Лебедева Е.Н., Красиков С.И., Зорин И.В., Кулагина Е.П., Николаева С.Н. Клинико-патогенетические аспекты повреждения почек при ожирении (Обзор литературы). Нефрология. 2014; 18(3): 24-33.
  131. Bagby S.P. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J. Am. Soc. Nephrol. 2004; 15: 2775-2791.
  132. Weinberg J.M. Lipotoxicity. Kidney Int. 2006; 70: 1560-1566.
  133. Wahba I.M., Mak R.H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2007; 2: 550-562.
  134. Gekle M. Renal tubule albumin transport. Annu. Rev. Physiol. 2005; 67: 573-594.
  135. Russo L.M., Sandoval R.M., McKee M., Osicka T.M., Collins A.B., Brown D., Molitoris B.A., Comper W.D. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 2007; 71: 504-513.
  136. Bobulescu I.A., Dubree M., Zhang J., McLeroy P., Moe O.W. Effect of renal lipid accumulation on proximal tubule Na+/H+ exchange and ammonium secretion. Am. J. Physiol. Renal Physiol. 2008; 294: F1315-F1322.
  137. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., Slezak L.A., Andersen D.K., Hundal R.S., Rothman D.L., Petersen K.F., Shulman G.I. Effects of free fatty acids on glucose transport and IRS-I-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 1999; 103: 253-259.
  138. Shulman G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 2000; 106: 171-176.
  139. Unger R.H. Lipotoxic diseases. Annu. Rev. Med. 2002; 53: 319-336.
  140. Thomas M.E., Morrison A.R., Schreiner G.F. Metabolic effects of fatty acid-bearing albumin on a proximal tubule cell line. Am. J. Physiol. Renal Fluid Electrolyte Physiol. 1995; 268: F1177-F1184.
  141. Birn H., Christensen E.I. Renal albumin absorption in physiology and pathology. Kidney Int. 2006; 69: 440-449.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##